Rakuten Medical Opens European Headquarters in the Netherlands
The clinical-stage biotechnology company has established European headquarters in the Netherlands to further strengthen its European operations
Rakuten Medical, a clinical-stage biotechnology company, has established its European headquarters in the Netherlands. The company decided to invest in Holland to accelerate its growth within Europe’s biotechnology sector.
Rakuten Medical develops precision-targeted cancer therapies based on its proprietary photoimmunotherapy (PIT) platform. With its new European headquarters in Amsterdam, the company will also make additional hires across the globe to support its European growth.
“Rakuten Medical is poised to become a fully integrated biotechnology company, and we are gearing up to build and commercialize a strong pipeline of anti-cancer therapies based on our proprietary photoimmunotherapy platform,” said Mickey Mikitani, chairman and CEO of Rakuten Medical. “Expanding our presence in Europe and Asia is critical for us to deliver upon our mission of conquering cancer, and delivering safe and effective treatments that could transform and improve the lives of patients globally.”
A Hotspot for Life Sciences and Health Innovation
The Netherlands is home to a robust life sciences and health industry, with Rakuten Medical being the latest addition to its roster of global innovators like Atricure and Johnson & Johnson. In fact, there are more than 2,900 life sciences and health companies operating in Holland that collectively employ over 34,000 people. In addition, the Netherlands supports 12 research universities, 85 hospitals and around 50 public-private partnerships between science, industry and government.
Source: PR Newswire4 June 2019